Antitumor effect of suberoylanilide hydroxamic acid and topotecan in renal cancer cells

Oncology Research

Volumn 19, Issue 5, 2011, Pages 217-233

  Sato, Akinori ^a   Asano, Takako ^a   Horiguchi, Akio ^a   Ito, Keiichi ^a   Sumitomo, Makoto ^a   Asano, Tomohiko ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

Histone deacetylase (HDAC); Renal cancer; Suberoylanilide hydroxamic acid (SAHA); Topotecan

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 4; HISTONE DEACETYLASE; RETINOBLASTOMA PROTEIN; TOPOTECAN; VORINOSTAT; ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; KIDNEY CANCER; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; ACETYLATION; APOPTOSIS; CELL PROLIFERATION; DRUG ANTAGONISM; HUMAN; KIDNEY TUMOR; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ACETYLATION; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; CYCLIN-DEPENDENT KINASE 4; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; KIDNEY NEOPLASMS; TOPOTECAN;

EID: 79957474486     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504011X12970940207841     Document Type: Article

References (29)

1. Motzer, R. J.; Bander, N. H.; Nanus, D. M. Renal-cell carcinoma. N. Engl. J. Med. 335:865-875; 1996.
2. Escudier, B.; Eisen, T.; Stadler, W. M.; Szczylik, C.; Oudard, S.; Siebels, M.; Negrier, S.; Chevreau, C.; Solska, E.; Desai, A. A.; Rolland, F.; Demkow, T.; Hutson, T. E.; Gore, M.; Freeman, S.; Schwartz, B.; Shan, M.; Simantov, R.; Bukowski, R. M. TARGET Study Group: Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356:125-134; 2007.
3. Ratain, M. J.; Eisen, T.; Stadler, W. M.; Flaherty, K. T.; Kaye, S. B.; Rosner, G. L.; Gore, M.; Desai, A. A.; Patnaik, A.; Xiong, H. Q.; Rowinsky, E.; Abbruzzese, J. L.; Xia, C.; Simantov, R.; Schwartz, B.; O'Dwyer, P. J. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24:2505-2512; 2006.
4. J. Clin. Oncol. 24:2505-2512; 2006.
5. Luu, T. H.; Morgan, R. J.; Leong, L.; Lim, D.; McNamara, M.; Portnow, J.; Frankel, P.; Smith, D. D.; Doroshow, J. H.; Wong, C.; Aparicio, A.; Gandara, D. R.; Somlo, G. A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: A California Cancer Consortium study. Clin. Cancer Res. 14:7138-7142; 2008.
6. Vansteenkiste, J.; Van Cutsem, E.; Dumez, H.; Chen, C.; Ricker, J. L.; Randolph, S. S.; Schöffski, P. Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. Invest. New Drugs 26:483-488; 2008.
7. Blumenschein, Jr., G. R.; Kies, M. S.; Papadimitrakopoulou, V. A.; Lu, C.; Kumar, A. J.; Ricker, J. L.; Chiao, J. H.; Chen, C.; Frankel, S. R. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/ or metastatic head and neck cancer. Invest. New Drugs 26:81-87; 2008.
8. Law, T. M.; Ilson, D. H.; Motzer, R. J. Phase II trial of topotecan in patients with advanced renal cell carcinoma. Invest. New Drugs 12:143-145; 1994.
9. Bruzzese, F.; Rocco, M.; Castelli, S.; Di Gennaro, E.; Desideri, A.; Budillon, A. Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis. Mol. Cancer Ther. 8:3075-87; 2009.
10. Vindelov, L. L.; Christensen, I. J.; Nissen, N. I. A detergent- trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 3:323-327; 1983.
11. Lehrmann, H.; Pritchard, L. L.; Harel-Bellan, A. Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation. Adv. Cancer Res. 86:41-65; 2002.
12. Wade, P. A. Transcriptional control at regulatory check- points by histone deacetylases: Molecular connections between cancer and chromatin. Hum. Mol. Genet. 10:693-698; 2001.
13. Cress, W. D.; Seto, E. Histone deacetylases, transcriptional control, and cancer. J. Cell. Physiol. 184:1-16; 2000.
14. Timmermann, S.; Lehrmann, H.; Polesskaya, A.; HarelBellan, A. Histone acetylation and disease. Cell. Mol. Life Sci. 58:728-736; 2001.
15. Yoo, C. B.; Jones, P. A. Epigenetic therapy of cancer: Past, present and future. Nat. Rev. Drug Discov. 5:37-50; 2006.
16. Richon, V. M.; Webb, Y.; Merger, R.; Sheppard, T.; Jursic, B.; Ngo, L.; Civoli, F.; Breslow, R.; Rifkind, R. A.; Marks, P. A. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc. Natl. Acad. Sci. USA 93:5705-5708; 1996.
17. Eckardt, J. R. Emerging role of weekly topotecan in recurrent small cell lung cancer. Oncologist 9(Suppl. 6):25-32; 2004.
18. McGuire, W. P.; Blessing, J. A.; Bookman, M. A.; Lentz, S. S.; Dunton, C. J. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study. J. Clin. Oncol. 18:1062-1067; 2000.
19. Moore, D. H. Chemotherapy for recurrent cervical carcinoma. Curr. Opin. Oncol. 18:516-519; 2006.
20. Bali, P.; Pranpat, M.; Swaby, R.; Fiskus, W.; Yamaguchi,H.; Balasis, M.; Rocha, K.; Wang, H. G.; Richon, V.; Bhalla, K. Activity of suberoylanilide hydroxamic acid against human breast cancer cells with amplification of her-2. Clin. Cancer Res. 11:6382-6389; 2005.
21. Sato, A.; Ito, K.; Asano, T.; Sumitomo, M.; Asano, T.; Hayakawa, M. Topotecan and small interfering RNA suppress survivin expression synergistically in Caki-1 renal cancer cells: Direct suppression of survivin and enhancement of transfection efficiency by topotecan. Int. J. Oncol. 32:171-176; 2008.
22. Griffith, T. S.; Kemp, T. J. The topoisomerase I inhibitor topotecan increases the sensitivity of prostate tumor cells to TRAIL/Apo-2L-induced apoptosis. Cancer Chemother. Pharmacol. 52:175-184; 2003.
23. Sato, A.; Oya, M.; Ito, K.; Mizuno, R.; Horiguchi, Y.; Umezawa, K.; Hayakawa, M.; Murai, M. Survivin associates with cell proliferation in renal cancer cells: Regulation of survivin expression by insulin-like growth factor- 1, interferon-gamma and a novel NF-kappaB inhibitor. Int. J. Oncol. 28:841-846; 2006.
24. Ramp, U.; Krieg, T.; Caliskan, E.; Mahotka, C.; Ebert, T.; Willers, R.; Gabbert, H. E.; Gerharz, C. D. XIAP expression is an independent prognostic marker in clear-cell renal carcinomas. Hum. Pathol. 35:1022-1028; 2004.
25. Gui, C. Y.; Ngo, L.; Xu, W. S.; Richon, V. M.; Marks, P. A. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc. Natl. Acad. Sci. USA 101: 1241-1246; 2004.
26. Richon, V. M.; Sandhoff, T. W.; Rifkind, R. A.; Marks, P. A. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. USA 97:10014-10019; 2000.
27. Hrzenjak, A.; Moinfar, F.; Kremser, M. L.; Strohmeier, B.; Staber, P. B.; Zatloukal, K.; Denk, H. Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells. Mol. Cancer Ther. 5:2203-2210; 2006.
28. Glozak, M. A.; Sengupta, N.; Zhang, X.; Seto, E. Acetylation and deacetylation of non-histone proteins. Gene 363: 15-23; 2005.
29. Xu, W. S.; Parmigiani, R. B.; Marks, P. A. Histone deacetylase inhibitors: Molecular mechanisms of action. Oncogene 26:5541-5552; 2007.